Towards a European strategy to address the COVID-19 pandemic

Viola Priesemann; Rudi Balling; Simon Bauer; Philippe Beutels; André Calero Valdez; Sarah Cuschieri; Thomas Czypionka; Uga Dumpis; Enrico Glaab; Eva Grill; Pirta Hotulainen; Emil N. Iftekhar; Jenny Krutzinna; Christos Lionis; Helena Machado; Carlos Martins; Martin McKee; George N. Pavlakis; Matjaž Perc; Elena Petelos; Martyn Pickersgill; Barbara Prainsack; Joacim Rocklöv; Eva Schernhammer; Ewa Szczurek; Sotirios Tsiodras; Steven Van Gucht; Peter Willeit

doi:10.1016/S0140-6736(21)01808-0

Towards a European strategy to address the COVID-19 pandemic

Viola Priesemann, Rudi Balling, Simon Bauer, Philippe Beutels, André Calero Valdez, Sarah Cuschieri, Thomas Czypionka, Uga Dumpis, Enrico Glaab, Eva Grill, Pirta Hotulainen, Emil N. Iftekhar, Jenny Krutzinna, Christos Lionis, Helena Machado, Carlos Martins, Martin McKee, George N. Pavlakis, Matjaž Perc, Elena PetelosMartyn Pickersgill, Barbara Prainsack, Joacim Rocklöv, Eva Schernhammer, Ewa Szczurek, Sotirios Tsiodras, Steven Van Gucht, Peter Willeit

Institute of Multimedia and Interactive Systems

43 Citations (Scopus)

Original language	English
Journal	The Lancet
Volume	398
Issue number	10303
Pages (from-to)	838-839
Number of pages	2
ISSN	0140-6736
DOIs	https://doi.org/10.1016/S0140-6736(21)01808-0
Publication status	Published - 04.09.2021

Funding

RB is a shareholder of the Information Technology For Translational Medicine research institute. SB reports grants from Netzwerk Universitätsmedizin. PB reports grants from the EU's SC1-PHE-CORONAVIRUS-2020 programme, Pfizer, GlaxoSmithKlein, and European Commission IMI, unrelated to this Correspondence. CL reports grants from the University of Oxford, the National Centre for Smoking Cessation and Training, Gilead Sciences, and the European Commission's Horizon 2020, unrelated to this Correspondence, all under the agreement and control of the Special Committee for Research Grants of the University of Crete, Greece. GNP's contribution is in his personal capacity; the opinions expressed are the author's own and do not reflect the views of the National Institutes of Health (NIH), the Department of Health and Human Services, or the US Government. GNP's patents and company interactions are managed through the NIH. EP reports grants from the European Commission and personal fees from the European Commission, Maastricht University, Charité – Universitätsmedizin Berlin, and the Swedish Healthcare Academy, unrelated to this Correspondence. MPi reports grants and personal fees from Wellcome and the Economic and Social Research Council, grants from the Medical Research Council, and personal fees from the Research Foundation Flanders, unrelated to this Correspondence. BP is a member of the Austrian National Bioethics Committee and has been a member of the European Group on Ethics in Science and New Technologies (2017–21). Projects in the laboratory of ESz are co-funded by Merck Healthcare. All other authors declare no competing interests. Acknowledgements of funding sources are stated in the appendix . Additional information about the estimation of ICU admissions and translated versions of this Correspondence is available in the appendix.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(21)01808-0

Cite this

Priesemann, V., Balling, R., Bauer, S., Beutels, P., Valdez, A. C., Cuschieri, S., Czypionka, T., Dumpis, U., Glaab, E., Grill, E., Hotulainen, P., Iftekhar, E. N., Krutzinna, J., Lionis, C., Machado, H., Martins, C., McKee, M., Pavlakis, G. N., Perc, M., ... Willeit, P. (2021). Towards a European strategy to address the COVID-19 pandemic. The Lancet, 398(10303), 838-839. https://doi.org/10.1016/S0140-6736(21)01808-0

@article{e5d06711c38d4e20ae0af45f22604138,

title = "Towards a European strategy to address the COVID-19 pandemic",

author = "Viola Priesemann and Rudi Balling and Simon Bauer and Philippe Beutels and Valdez, \{Andr{\'e} Calero\} and Sarah Cuschieri and Thomas Czypionka and Uga Dumpis and Enrico Glaab and Eva Grill and Pirta Hotulainen and Iftekhar, \{Emil N.\} and Jenny Krutzinna and Christos Lionis and Helena Machado and Carlos Martins and Martin McKee and Pavlakis, \{George N.\} and Matja{\v z} Perc and Elena Petelos and Martyn Pickersgill and Barbara Prainsack and Joacim Rockl{\"o}v and Eva Schernhammer and Ewa Szczurek and Sotirios Tsiodras and \{Van Gucht\}, Steven and Peter Willeit",

note = "Funding Information: RB is a shareholder of the Information Technology For Translational Medicine research institute. SB reports grants from Netzwerk Universit{\"a}tsmedizin. PB reports grants from the EU's SC1-PHE-CORONAVIRUS-2020 programme, Pfizer, GlaxoSmithKlein, and European Commission IMI, unrelated to this Correspondence. CL reports grants from the University of Oxford, the National Centre for Smoking Cessation and Training, Gilead Sciences, and the European Commission's Horizon 2020, unrelated to this Correspondence, all under the agreement and control of the Special Committee for Research Grants of the University of Crete, Greece. GNP's contribution is in his personal capacity; the opinions expressed are the author's own and do not reflect the views of the National Institutes of Health (NIH), the Department of Health and Human Services, or the US Government. GNP's patents and company interactions are managed through the NIH. EP reports grants from the European Commission and personal fees from the European Commission, Maastricht University, Charit{\'e} – Universit{\"a}tsmedizin Berlin, and the Swedish Healthcare Academy, unrelated to this Correspondence. MPi reports grants and personal fees from Wellcome and the Economic and Social Research Council, grants from the Medical Research Council, and personal fees from the Research Foundation Flanders, unrelated to this Correspondence. BP is a member of the Austrian National Bioethics Committee and has been a member of the European Group on Ethics in Science and New Technologies (2017–21). Projects in the laboratory of ESz are co-funded by Merck Healthcare. All other authors declare no competing interests. Acknowledgements of funding sources are stated in the appendix . Additional information about the estimation of ICU admissions and translated versions of this Correspondence is available in the appendix. ",

year = "2021",

month = sep,

day = "4",

doi = "10.1016/S0140-6736(21)01808-0",

language = "English",

volume = "398",

pages = "838--839",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "10303",

}

Priesemann, V, Balling, R, Bauer, S, Beutels, P, Valdez, AC, Cuschieri, S, Czypionka, T, Dumpis, U, Glaab, E, Grill, E, Hotulainen, P, Iftekhar, EN, Krutzinna, J, Lionis, C, Machado, H, Martins, C, McKee, M, Pavlakis, GN, Perc, M, Petelos, E, Pickersgill, M, Prainsack, B, Rocklöv, J, Schernhammer, E, Szczurek, E, Tsiodras, S, Van Gucht, S & Willeit, P 2021, 'Towards a European strategy to address the COVID-19 pandemic', The Lancet, vol. 398, no. 10303, pp. 838-839. https://doi.org/10.1016/S0140-6736(21)01808-0

TY - JOUR

T1 - Towards a European strategy to address the COVID-19 pandemic

AU - Priesemann, Viola

AU - Balling, Rudi

AU - Bauer, Simon

AU - Beutels, Philippe

AU - Valdez, André Calero

AU - Cuschieri, Sarah

AU - Czypionka, Thomas

AU - Dumpis, Uga

AU - Glaab, Enrico

AU - Grill, Eva

AU - Hotulainen, Pirta

AU - Iftekhar, Emil N.

AU - Krutzinna, Jenny

AU - Lionis, Christos

AU - Machado, Helena

AU - Martins, Carlos

AU - McKee, Martin

AU - Pavlakis, George N.

AU - Perc, Matjaž

AU - Petelos, Elena

AU - Pickersgill, Martyn

AU - Prainsack, Barbara

AU - Rocklöv, Joacim

AU - Schernhammer, Eva

AU - Szczurek, Ewa

AU - Tsiodras, Sotirios

AU - Van Gucht, Steven

AU - Willeit, Peter

N1 - Funding Information: RB is a shareholder of the Information Technology For Translational Medicine research institute. SB reports grants from Netzwerk Universitätsmedizin. PB reports grants from the EU's SC1-PHE-CORONAVIRUS-2020 programme, Pfizer, GlaxoSmithKlein, and European Commission IMI, unrelated to this Correspondence. CL reports grants from the University of Oxford, the National Centre for Smoking Cessation and Training, Gilead Sciences, and the European Commission's Horizon 2020, unrelated to this Correspondence, all under the agreement and control of the Special Committee for Research Grants of the University of Crete, Greece. GNP's contribution is in his personal capacity; the opinions expressed are the author's own and do not reflect the views of the National Institutes of Health (NIH), the Department of Health and Human Services, or the US Government. GNP's patents and company interactions are managed through the NIH. EP reports grants from the European Commission and personal fees from the European Commission, Maastricht University, Charité – Universitätsmedizin Berlin, and the Swedish Healthcare Academy, unrelated to this Correspondence. MPi reports grants and personal fees from Wellcome and the Economic and Social Research Council, grants from the Medical Research Council, and personal fees from the Research Foundation Flanders, unrelated to this Correspondence. BP is a member of the Austrian National Bioethics Committee and has been a member of the European Group on Ethics in Science and New Technologies (2017–21). Projects in the laboratory of ESz are co-funded by Merck Healthcare. All other authors declare no competing interests. Acknowledgements of funding sources are stated in the appendix . Additional information about the estimation of ICU admissions and translated versions of this Correspondence is available in the appendix.

PY - 2021/9/4

Y1 - 2021/9/4

UR - https://www.scopus.com/pages/publications/85114192869

U2 - 10.1016/S0140-6736(21)01808-0

DO - 10.1016/S0140-6736(21)01808-0

M3 - Letters

C2 - 34384539

AN - SCOPUS:85114192869

SN - 0140-6736

VL - 398

SP - 838

EP - 839

JO - The Lancet

JF - The Lancet

IS - 10303

ER -

Towards a European strategy to address the COVID-19 pandemic

Funding

UN SDGs

Access to Document

Other files and links

infoXpand: Modeling Network: infoXpand - Information, Opinions, Mobility, Behavior, and Bayesian Inference in Infectious Disease Modeling - Subproject C

Cite this